. [6], Martin has worked with the Federal government of the United States in a number of capacities. John C. Martin May 7, 1951-March 30, 2021 Palo Alto, California. Leave a sympathy message to the family on the memorial page of John Martin to pay them a last tribute. October 28, 2022 (81 years old) View obituary. "It funded a number of scientists' projects in the developing world," Lange said. John would later be seen at the picnic chatting with employees, watching others play volleyball and eating barbecue. When I was asked to lead Medical Affairs a few months before the introduction of Gileads first HIV drug, tenofovir (Viread), John handed me a business card of a physician he had recently met in one of the largest HIV-treating practices in New Yorks Greenwich Village. Gilead jolted the industry with several major scientific breakthroughs, beginning with the development of the first anti-influenza pill, Tamiflu, which the company licensed to the Swiss drugmaker Hoffman-La Roche in 1996. On behalf of all of us at Gilead, I extend our deepest condolences to Johns family.. Make a life-giving gesture Embarcadero Media Staff Writer Sue Dremann contributed to this report. While Hughley is not a patient, hes connected to cancer through his father and sister, and hes also a vocal advocate for equitable health care. Close. "It was just a dream really. John C. Martin Sign up for the Peninsula Foodist newsletter. Palo Alto Online - Lasting Memories - John C. Martin's memorial The companys HIV drugs have also been enormously successful, helping turn that disease into a more treatable, albeit chronic condition. John C. Martin, who became a billionaire by developing and marketing a daily single-dose pill that transformed H.I.V. John began his career at Gilead in 1990, as vice president of Research & Development. During his time with Gilead, Martin also expanded access to HIV medication in developing countries. A chemist by training, he turned Gilead Sciences into a leading, and lucrative, innovator with single-pill treatments for H.I.V. He argued, among other things, that high prices for successful products were needed to subsidize future research. John handled these issues with aplomb working methodically behind the scenes. This is not a complete listing of all burials in this cemetery. He used the opportunity to conduct his own market research to help the drive the companys clinical development pipeline strategy, anticipate objections to product adoption or exploit opportunities to position Gileads products more favorably vis--vis our competitors. "[12], Sofosbuvir is cited as an example of how specialty drugs present both benefits and challenges. John expected that the top researchers and clinicians would personally know the top managers at Gilead. Martin is survived by his partner, Lillian Lou, two children and three siblings, according to Johnson. drugs. Some of his accolades include the American Chemical Society's Horace S. Isbell Award, which acknowledges significant research in carbohydrate chemistry and biochemistry; the International Society for Antiviral Research's Gertrude B. Elion Award for Scientific Excellence; and a Lifetime Achievement Award for Public Service from the Institute of Human Virology at the University of Maryland School. Some had to be taken with food, some without. Published: Mar 31, 2021 Yes, we talked shop at the company picnic. One of the first things he did was drop the antisense oligonucleotide work. John set the example himself. Comedian and radio show host D.L. Powered by Madgex Job Board Software. Cynthia Muir. But the small talk of those huddled around him inevitably turned, and as most casual conversations almost always did with John, to the excitement of the work. In 1978, he joined Syntex Laboratories, which was headquartered in Palo Alto. In 1978, he joined Syntex Laboratories, which was headquartered in Palo Alto. Martin joined Gilead in 1990. It was this belief that later led to Gilead's launch of tenofovir, trademarked as Viread, which was approved by the U.S. Federal Drug Administration as an anti-HIV treatment in 2001. John C. Martin, who became a billionaire by developing and marketing a daily single-dose pill that transformed H.I.V. John Martin Obituary - John Martin Death : Gilead CEO Dies: Cause Of Death: Funeral- Gilead CEO, John Martin has died aged 70, on March, 2021, with loved ones left in total devastation. John C. Martin was an unassuming man with an ordinary name. He was a leader who listened and observed far more than he spoke. John began his career at Gilead in 1990, as vice president of Research & Development. He was more likely to be touting the latest approved drug or the importance of a recent company initiative. To send a flower arrangement or to plant trees in memory of The campaign launched last year, targeting people in their 20s and 30s, Merz Aesthetics North America president Patrick Urban told Endpoints News at the time. John Martin - Vice President, North American / Latin - LinkedIn The Palo Alto Police Department confirmed in an email to this news organization that a man in his 60s appeared to have fallen in the area at around 6:30 p.m. John likely already knew the answer or had a better answer than what you might muster up. Become a Member According to a 2015 company report, Gilead had signed agreements with 11 India-based pharmaceutical manufacturers to develop generic versions of its hepatitis C medicine for 101 developing countries, from Afghanistan to Zimbabwe. Martin is credited as the editor.) Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company's chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019. It is with great sadness that the company has learned of the passing of Dr. Martin, whose scientific vision and leadership helped transform the lives of millions of patients and shape Gilead into the company that it is today. We extend our deepest sympathies to Johns family and everyone who was fortunate to have known him. Are you excited to go to the company picnic? I asked. In the companys CLEAR study of nearly 14,000 patients, Esperions drug Nexletol cut the combined risk of heart attack, stroke, cardiovascular death or the need for coronary revascularization by 13%, compared with placebo. Judge rules high school math policy violates state law, Following national trend, Palo Alto looks to establish gun-free zones, City: Pagemill Pastures' use of hydrant water was 'inadvertent' and occurred just once. All rights reserved. Your contribution matters. But the company attracted scrutiny from health care providers and the federal government during its growth. Longtime Gilead captain John Martin, mastermind of lifesaving HIV, hep Services honoring his life will also be held . https://www.businesswire.com/news/home/20210330006163/en/, Jacquie Ross, Investors Gilead, died September 15, 2021. Martin started at Gilead as a VP of R&D back in 1990, moving up to CEO only 6 years later as he helmed the company for a 20-year stretch before handing the reins to Milligan and sticking with the chairmans post until 2019. It is with great sadness that the company has learned of the passing of Dr. Martin, whose scientific vision and leadership helped transform the lives of millions of patients and shape Gilead into the company that it is today. John Martin Gilead Obituary - John Martin Gilead Death : Dead : Funeral : Cause Of Death - Gilead CEO, John Martin died aged 70, on March, 2021, with loved ones left in agony. Gileads drugs worked against the virus. November 5, 2022 (87 years old) View obituary. During Dr. Martins tenure, Gilead also created remdesivir in 2009, which proved ineffective in its original mission, to treat hepatitis C and other viruses, but which turned out to be a therapeutic weapon during the Covid-19 pandemic. [5] He served on the board of trustees of the latter two universities. He is survived by his wife, Allita M. Martin of the home; 3 children; 2 brothers; 2 sisters; a number of grandchildren. It seemed as if his mind never stopped working and he was always 10 steps ahead of everyone else. His death at the age of 69 was flagged by the company he built, though a. Endpoints News connected with the new chair of the generic industrys Association for Accessible Medicines, Christine Baeder, who is also Tevas COO, via video conference on Friday. Remembering John A. Rowland High School - Legacy.com John.https://t.co/VF7v1jluhg, John Maraganore (@JMaraganore) March 31, 2021, John was an amazing leader, my most influential mentor and embodied a biotech success culture that fueled Gileads success. From 1984 to 1990, he was the director of antiviral chemistry at Bristol-Myers Squibb. Martin, who had a background in chemical engineering and organic chemistry and had done a brief stint at Bristol-Myers Squibb, joined Gilead in 1990 with the pioneering idea that nucleotides could be used as an effective drug for HIV treatment. Advertising Info On behalf of the employees and Board of Directors at Kronos Bio, I am deeply saddened by Johns passing. May 7, 1951-March 30, 2021 John Martin Gilead Obituary: Gilead CEO, John Martin kicked the bucket matured 70, on March, 2021, with friends and family left in desolation. He was 69. Martin is credited as the editor.) Johns legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world, said Daniel ODay, who took over as CEO after Martin and his close colleague John Milligan left Gilead a couple of years ago. Sorry, but further commenting on this topic has been closed. John Wayne Martin, please click here to visit our Sympathy Store. "If you missed doses, the HIV virus could mutate and become resistant," said Lange, who continued to work on other projects with Martin after the sale of his company. Lawmakers", "The Increasing Impact of High-Cost Specialty Therapies", "New Expensive Treatments for Hepatitis C Infection", "John C. Martin, Gilead Chairman, joins the Board of Directors at The Scripps Research Institute - Scripps Research", "Prominent group of new University trustees includes Kilts, Lansing", "Ernst & Young Seeks Northern California Predominant Entrepreneurs", "Three Other Newly Elected Members of the National Academy of Engineering Are Part of the Viterbi Family", "John C. Martin, 69, Dies; Led Drugmaker in Breakthroughs", https://en.wikipedia.org/w/index.php?title=John_C._Martin_(businessman)&oldid=1139809686, This page was last edited on 17 February 2023, at 00:55. In 1978, he joined Syntex Laboratories, which was headquartered in Palo Alto. Promotions Before, patients receiving antiretroviral treatment could take up to 32 pills a day, said Lou Lange, a partner at Asset Management Ventures and founder of CV Therapeutics, a Palo Alto-based biotech company that was later sold to Gilead in 2009 for $1.4 billion. Rowland Heights, CA 91748. JOHN MARTIN OBITUARY MOUNT AIRY Mr. John Kerr Martin, age 56, of Mount Airy, passed away Monday May 12, 2014, after a long period of declining health. All rights reserved. [10], In 2014, Martin led the commercialization of Sovaldi (sofosbuvir) Vivek Ramaswamy, the former CEO of Roivant who stepped down earlier this year, called Martin one of those rare industry leaders who said what he believed, rather than what others wanted to hear. In his Twitter post, Ramaswamy cared about solving problems, regardless of how he may be perceived as he went about it. Gilead toiled on this work for more than a decade before acquiring Pharmasset and finishing work on what became the dominant cure for HCV. Leading Gilead's success is John Martin, CEO since 1996. [4][1] Gilead is known for developing drugs such as Atripla (for HIV/AIDS) and commercializing Sovaldi (sofosbuvir) for the treatment of the liver virus hepatitis C. Martin is the recipient of a number of awards, including the Biotechnology Heritage Award (2017). But his most notable contributions to the company came after he was named CEO in 1996. His marriage to Ms. Martin ended in divorce. John C. Martin, who led Gilead to greatness in developing a hugely profitable HIV drug franchise, has died. Terms of Use Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the companys chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019. February 7, 1985 - February 26, 2023. Born on May 7, 1951, in Easton, Pennsylvania, Martin received his bachelor's degree in chemical engineering from Purdue University, a master's degree in marketing from Golden Gate University, and a doctorate in organic chemistry from the University of Chicago. [1], Martin joined the American biotechnology company Gilead Sciences in 1990 as its vice president for research and development. All Magrolimab Studies Re-Opening for Patient Enrollment in the U.S. Gilead Statement on WHO Recommendation of Veklury (Remdesivir) and Acceleration of Prequalification Submission, Gilead Implements Contract Pharmacy Integrity Initiative for Branded Hepatitis C Products, Gilead Expands Availability of Veklury (remdesivir) to Non-Hospital Outpatient Facilities, Gilead Announces Global Resolution of Bictegravir Patent Dispute with ViiV Healthcare, Gilead Announces Actions to Remove Counterfeit HIV Medications from US Supply Chain, Gilead Statement on Zydelig U.S. Let me correct that: I was often second, because John was already there. "[19], The 2014 Lifetime Achievement Award for Public Service was presented to John Martin by the Institute of Human Virology at the University of Maryland School of Medicine, for his work on the development of anti-HIV medications and on AIDS prevention through Pre-exposure prophylaxis. Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the companys chief executive officer from 1996 to 2016 and as its chairman from 2008 to 2019. While some of us left Gilead prior to Johns departure at the end of 2018 (I left in 2005), there was quite an exodus in recent years of senior leaders who spent the bulk of their careers at Gilead and have now moved on to be CEOs and board members for other companies. Martin's death was announced by Gilead, where he served as CEO from 1996 to 2016. By making it easier for patients to self-medicate, they were more likely to take the full doses that were prescribed, reducing the risk that they could become breeding grounds for drug-resistant strains of the disease. A quarters-long flurry of layoffs has caused thousands of workers in life sciences to go hunting for their next position sooner than expected, and the latest wave could make it more difficult to get new offers in hand in short order. Fly to New York the next weekend to meet him, John said. He stepped down as CEO in 2016 but maintained a role in the company as executive chairman from 2016 to 2018. I dragged my feet for a year, with the lame excuse that I was too busy to move my things to a new office. Circulation & Delivery, About Us Cancel anytime. In his last major act as CEO, Martin oversaw the acquisition of Kite Pharma and its CAR-T platform to strengthen the companys oncology and cell therapy bona fides. John Martin, the chief executive officer who turned Gilead Sciences into a powerhouse company with treatments for hepatitis and HIV, died. FOSTER CITY, Calif.-- ( BUSINESS WIRE )--Gilead Sciences, Inc. (Nasdaq: GILD) today released the following statement on the death of John C. Martin, PhD, who served as the company's chief. Cremation. [6], Martin was director of antiviral chemistry at Bristol-Myers Squibb from 1984 to 1990. Martin is believed to have fallen while walking near Coleridge Avenue and Bryant Street on March 29, said Franklin Johnson, founder of Asset Management Company and a close friend of Martin, in an email. The pill combined two of the most prescribed AIDS medications at the time Gilead's Truvada and Bristol-Myers Squibb's Sustiva and was set at a price of $1,100 a month. During my tenure at Gilead (1997-2005), Martins office was austere. Sports View Tribute Book "[6], In 2003, Martin received the International Society for Antiviral Research's Gertrude B. Elion Award for Scientific Excellence in 2003. His tenure in the pharmaceutical industry spanned at least four decades. We will seek to fill it with gratitude for his remarkable life and work to honor him in all we do. He didnt focus on selling a future vision of Gilead. "We developed the drug; we invented it.". Born in Alleghany County, VA, Mr. Martin was born February 20, 1948, the son of Arthur Mason and Vivian Cash Martin. Death / Obituaries. Mobile site. Martin, who had a background in chemical engineering and organic chemistry and had done a brief stint at Bristol-Myers Squibb, joined Gilead in 1990 with the pioneering idea that nucleotides could be used as an effective drug for HIV treatment. Visitor Info, Send News Tips It is with great sadness that the company has learned of the passing of Dr. Martin, whose scientific vision and leadership helped transform the lives of millions of patients and shape Gilead into the company that it is today. John didnt try to persuade with a dynamic or stylized narrative, but rather by clearly communicating a core idea in the simplest and most straight-forward manner possible, often with just a short statement or a Socratic question. [13], Martin was president of the International Society for Antiviral Research (1998-2000); chairman of the California Healthcare Institute (2005-2006, 2009); and chairman of BayBio (1999-2001). Competitors included GSK, BMS, Pfizer, Abbott, Roche, and Merck. Sorry, you have Javascript Disabled! The singer-songwriter and actress is the latest celebrity addition to Merz Aesthetics Beauty on Your Terms campaign for Botox rival Xeomin. He was born Jul. Obituary information for John R. Martin He was a resident of Old Palo Alto. John Martin, the chief executive officer who turned Gilead Sciences into a powerhouse company with treatments for hepatitis and HIV, died. [5], Martin worked at Syntex Corporation from 1978 to 1984. [20], Last edited on 17 February 2023, at 00:55, Pandemic Perspectives with John C. Martin, President's Emergency Plan for AIDS Relief, International Society for Antiviral Research, National Institute of Allergy and Infectious Diseases, Centers for Disease Control and Prevention, Presidential Advisory Council on HIV/AIDS, "Gilead's John C. Martin: One Breakthrough Drug After Another", "John Martin: Executive Profile & Biography - Businessweek", "FDA Approves Gilead, Bristol-Myers Squibb Once-a-Day Combination Antiretroviral Pill", "Atripla (Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate) Tablets", "HIV/AIDS Historical Time Line 2000 - 2010", "Gilead's John Martin scores 'best CEO' trophy for huge stock gains", "Gilead's $84,000 Treatment Questioned by U.S. But the company attracted scrutiny from health care providers and the federal government during its growth. According to the New York Times, the Justice Department could seek billions of dollars in royalties for Gilead's previous sales of the drug, which brings in about $3 billion each year for the company.Gilead rejected the government's complaint and has maintained that the patents were invalid. Kevin Hou. John hungered for this kind of market knowledge so much, that he wanted it woven into the companys cultural fabric. Queen of Heaven Cemetery - Los Angeles County, California - Interment.net Hemolytic Anemia Sales Specialist, Rare Genetic Diseases, Biotech pioneer and startup investor John Martin, who built Gilead into a powerhouse player, has died, Digital therapeutics: The key to maximizing the potential of medicinal assets, What latest wave of layoffs means for biotech; Radiotherapy shortage; Delivering on mRNA's promises; and more, Harder to find homes: Latest wave of biotech layoffs could test the industry, Esperion unveils long-awaited data on cholesterol pill's ability to cut cardiovascular risk, A radioactive prostate cancer therapy is a last lifeline for patients. He was 69. Place a Legal Notice 1996-2023 Gilead Sciences, Inc. All rights reserved. Gileads work on H.I.V. Simply scheduling a daily regimen was a burdensome task and made it difficult for patients to fully adhere to prescriptions needed to keep the virus in check. Alice Bertha Anderson. [15], In 1990,[16] Martin received the American Chemical Society's Isbell Award, "for his applications of carbohydrate chemistry to the design of medicinally active nucleosides and nucleotides. A memorial service will be held at a later date. Yet he left a legacy of having built one of biotechs most successful and enduring companies. Born on May 7, 1951, in Easton, Pennsylvania, Martin received his bachelor's degree in chemical engineering from Purdue University, a master's degree in marketing from Golden Gate University, and a doctorate in organic chemistry from the University of Chicago. Thats My Word is tackling disparities in multiple myeloma diagnosis and treatment in the Black community. John C. Martin, pioneer of single-pill HIV treatment, dies unexpectedly But Martin, 59, . JOHN MARTIN | Obituaries | montgomeryherald.com Martin oversaw a period of growth in the company when Gilead essentially created a cure for hepatitis C, which generated an enormous revenue stream for the company with its powerhouse drugs, Harvoni and Sovaldi. John unified Gilead around the easy-to-understand vision of one pill, once a day. It became the north star for the company. Martins death was announced by Gilead, where he served as CEO from 1996 to 2016. Queen of Heaven CemeteryRowland Heights, Los Angeles County, California. [11] Gilead, died Wednesday, September 15, 2021 at his residence. John Martin Gilead Obituary / Death : We mourn with the family of John Martin, we understand how disheartening they could be right now, so we are sending our thoughts and prayers to the affected. In addition to running Gilead, Dr. Martin was president of the International Society for Antiviral Research from 1998 to 2000. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. In 2014, Democrat lawmakers asked Martin to justify the company's $84,000 price tag of its hepatitis C drug, Sovaldi, which is equivalent to $1,000 per pill. Before, patients receiving antiretroviral treatment could take up to 32 pills a day, said Lou Lange, a partner at Asset Management Ventures and founder of CV Therapeutics, a Palo Alto-based biotech company that was later sold to Gilead in 2009 for $1.4 billion. Obituary information for John Martin "Marty" Murphy Martin, a trained chemist, joined Gilead in 1990, and moved from its research director to chief executive in six years, according to the Times.He served as CEO from 1996 to 2016, and was executive chairman from 2016 until his 2018 retirement. His tenure in the pharmaceutical industry spanned at least four decades. Martin is credited as the editor.) John C. Martin, who led Gilead to greatness in developing a hugely profitable HIV drug franchise, has died. But his most notable contributions to the company came after he was named CEO in 1996.Of note is the development of Atripla, the first single-tablet regimen for treating HIV, which hit the market in 2006. Courtesy Lou Lange. "So a single pill once a day is a huge step forward.". The Ruth family will greet friends from 4 - 7 p.m. on Thursday, August 18, 2022, at the Pleasant Grove Church of Christ, 7197 Co. Rd. Print Edition/Archives Martin is believed to have fallen while walking near Coleridge Avenue and Bryant Street on March 29, said Franklin Johnson, founder of Asset Management Company and a close friend of Martin, in an email. December 1, 2022 (89 years old) View obituary. When I was tasked with leading Gilead Medical Affairs, I was supposed to move to the R&D building where my new boss, Norbert Bischofberger, was located. Every month, he would visit clinicians, often with a Gilead sales rep. However, in April 2014, U.S. House Democrats Henry Waxman, Frank Pallone Jr., and Diana DeGette wrote Martin questioning the $84,000 price for Sovaldi. "We weren't making money or anything," Samuel said. But his leadership qualities and accomplishments as a biopharma CEO were extraordinary. On behalf of all of us at Gilead, I extend our deepest condolences to Johns family.. "As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth," Gilead wrote in a statement announcing Martin's death.During his time with Gilead, Martin also expanded access to HIV medication in developing countries. He read philosophy with practical aims in mind. While at Syntex, he decided to strengthen his business understanding and pursued an MBA in Marketing from Golden Gate University. [2] [3] He joined Gilead Sciences in 1990 as vice president for research and development. The cause was head injuries suffered the day before, when he fell on a sidewalk while walking home in Old Palo Alto, according to the Santa Clara County medical examiner. Gilead Sciences : Comments on the Passing of John C. Martin, PhD John C. Martin, former CEO of Gilead Sciences who helped develop the first once-a-day pill to treat HIV while at the helm of the company, died unexpectedly on March 30 after suffering head injuries from a fall the previous day. He was 69. TheSixFifty.com Under Martin's leadership, Gilead also developed the first anti-influenza pill, Tamiflu, which was licensed to Hoffmann-La Roche, a Swiss health care company; and Truvada, which was approved by the FDA to treat HIV in 2004 and for HIV infection prevention in 2012. Born on May 7, 1951, in Easton, Pennsylvania, Martin received his bachelor's degree in chemical engineering from Purdue University, a master's degree in marketing from Golden Gate University, and a doctorate in organic chemistry from the University of Chicago. My first few months at Gilead were spent traveling the world visiting every top expert HBV clinician to learn about the disease, the current state of treatment and what outcomes would be most meaningful. With those pieces in place, Gilead was on its way to dominating the HIV marketplace. "As chief executive officer from 1996 through 2016, he steered the company through a period of remarkable growth," Gilead wrote in a statement announcing Martin's death. With that vision in mind, Gilead acquired Triangle Pharmaceuticals to obtain a second backbone nucleoside analogue to combine with Gileads own tenofovir. John R. Martin John R. Martin, age 84, of Winterhaven, CA, passed away Dec. 22, 2022 in Yuma, AZ. Nominations are now open for a special report that will highlight the contributions of LGBTQ+ biopharma leaders. John Martin Gilead Obituary: Gilead - Naija campus jams | Facebook 46, Mount Gilead. Framed group photos highlighting Gileads history decorated the walls. But the little biotech from Foster City, California, over the course of a decade, reigned supreme as the worlds largest maker of HIV medicines. "We weren't making money or anything," Samuel said. https://t.co/1gMZa5YtRX, Chris Garabedian (@cngarabedian) March 31, 2021, Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation John told me he had planted the seed and that I just needed to convince the doctor that he could impact more patient lives by helping to educate other clinicians on his experience and how they could treat their patients optimally using Gileads drugs. John decided to join the United States Marine Corp after High School and served his Country honorably. Martin joined Gilead in 1990. SO sad about passing of John Martin. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data For more information on Gilead Sciences, please visit the companys website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. Johns legacy will be felt for generations to come, living on through the scientific progress made under his leadership and the programs he championed that expanded access to medications for people around the world, Daniel ODay, chairman and current CEO of Gilead Sciences said in a statement.

Domee Shi Husband, Alex Cooper Lauren Leaving, Spanish Revival Furniture For Sale, Japanese Matchlock Reproduction, Articles J